The U.S. Food and Drug Administration (FDA) has officially asked the Drug Enforcement Administration (DEA) to schedule 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance. The FDA has taken this action because of increasing worries about 7-OH safety and its potential for abuse and its impact on public health. The synthetic compound 7-OH shows more opioid-like properties than natural kratom leaf alkaloids which has led regulatory bodies to support tighter control measures for consumer protection and health-conscious product development. This announcement was made on July 29, 2025.
FDA Recommends Scheduling of Synthetic 7-Hydroxymitragynine (7-OH) from Kratom
The U.S. Food and Drug Administration (FDA) has officially asked the Drug Enforcement Administration (DEA) to schedule 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance. The FDA has taken this action because of increasing worries about 7-OH safety and its potential for abuse and its impact on public health. The synthetic compound 7-OH shows more opioid-like properties than natural kratom leaf alkaloids which has led regulatory bodies to support tighter control measures for consumer protection and health-conscious product development. This announcement was made on July 29, 2025.
Drug Enforcement Administration (DEA) and Kratom Overview
- The Drug Enforcement Administration (DEA) is a U.S. federal law enforcement agency under the Department of Justice, responsible for controlling drug trafficking and enforcement of the Controlled Substances Act.
- Established in 1973, it coordinates drug investigations domestically and internationally.
- The DEA is the primary agency enforcing federal drug laws in the United States.[1]
Kratom (Mitragyna speciosa)
- Kratom is a large evergreen tree native to Southeast Asia, belonging to the Rubiaceae family.
- Traditionally used for medicinal and recreational purposes.
- At low doses, kratom produces stimulant-like effects, while at higher doses, it has opioid-like sedative effects.
- Use of kratom can result in adverse effects such as seizures, hallucinations, and liver damage. [2]
7-Hydroxymitragynine (7-OH)
- 7-OH is a terpenoid indole alkaloid found naturally in kratom leaves.
- Scientifically identified in 1994.
- The human body metabolizes 7-OH from mitragynine via liver enzyme oxidation.
- 7-OH exhibits stronger μ-opioid receptor binding than mitragynine.
- It has a high opioid-like potency, estimated as 10 to 13 times more potent than morphine.[3]
This elevated potency is a critical factor guiding innovation in lozenges and chewable nutraceutical formulation to ensure safety and efficacy in emerging kratom-derived products.
Regulatory Concerns and FDA Recommendations
The FDA’s recommendation targets concentrated or synthetic forms of 7-OH, not the natural compound present in trace amounts in kratom leaves. Key concerns include the following:
- 7-OH is a potent opioid with a high potential for abuse, dependence, and respiratory depression due to strong mu-opioid receptor binding.
- The FDA is particularly worried about high-potency 7-OH products that are commercially available, including those marketed to children in forms such as gummies and ice cream cones.
- There are no FDA-approved drugs containing 7-OH, nor is it lawful to market 7-OH-containing products as dietary supplements.
- Cases of health complications tied to 7-OH exposure include addiction, anxiety, depression, gastrointestinal issues, seizures, and withdrawal symptoms.
These concerns emphasize the necessity of nutraceutical product formulation and vigilant product innovation that prioritize consumer safety.
Serious cause when uses the FDA restricted products (ADDICTION):
- People might attempt to use these products for self-treatment of their anxiety symptoms and their mood disorders and their pain and opioid withdrawal symptoms. The FDA has not approved any product containing 7-OH for treating any medical condition because they have not proven its safety or effectiveness.
- 7-OH products represent new opioid substances which have not received FDA approval. The exposure to 7-OH products leads to dangerous health complications.
- The FDA has documented multiple cases of dangerous side effects which occurred after people used 7-OH products. The side effects of 7-OH exposure include addiction and anxiety and depression and gastrointestinal problems and insomnia and seizures and withdrawal symptoms that cause restlessness and body pain and fatigue and irritability and cold sweats.
FDA role and warning about the 7-OH, synthetic alkaloids found in Kratom: [4]
Category | Details |
Key Announcement | “Today, we’re taking action on 7-OH as a critical step in the fight against opioid addiction,” said HHS Secretary Robert F. Kennedy Jr. He emphasized protecting youth health and advancing national wellness. |
FDA Commissioner Statement | Dr. Marty Makary, FDA Commissioner, stressed that vape shops throughout the U.S. sell 7-OH in concentrated doses. Makary cautioned that 7-OH is an opioid that is more potent than morphine and needs to be regulated so we do not enter a new era of opioids. |
Primary FDA Concern | Concentrated products that contain 7-OH and target children and teenagers are sold at vape shops, including gummies in fruit flavors, ice cream cones, and drink mixes that are sometimes mislabeled or disguised as kratom. |
Regulatory Action | The FDA issued warning letters to seven companies for illegally distributing products that contain 7-OH in various forms (tablets, gummies, drink mixes, and shots). |
Healthcare Warning | FDA also warned healthcare professionals about the health risks associated with 7-OH. |
DEA’s Role | DEA is reviewing FDA’s scheduling recommendation. The process includes a public comment period before finalizing any scheduling action. |
Industry & Trade Support | Major trade associations — AHPA, NPA, and AKA — supported FDA’s targeted action on synthetic 7-OH, emphasizing that natural kratom leaf should not be restricted. |
Industry Statement | Robert Marriott (AHPA) commended FDA and HHS for focusing on illicit, synthetic 7-OH. He reaffirmed AHPA’s policy against using synthesized 7-OH in consumables and endorsed responsible marketing of natural kratom products. |
Studies about the 7-OH alkaloids:
Opioid Potency of 7-Hydroxymitragynine (7-OH)
- Early studies have shown that 7-OH induces respiratory depression at over three times the potency of morphine.
- Other research indicates 7-OH binds to mu-opioid receptors with approximately 10-to-13-fold greater affinity than morphine. [5]
Metabolic Formation and Pharmacological Effects
- 7-OH is produced from mitragynine by liver enzymes called hepatic cytochrome P450.
- Unlike mitragynine, which acts through atypical opioid mechanisms, 7-OH behaves as a conventional opioid agonist.
- Its opioid effects include those that can be reversed by naloxone and involve the risk of tolerance and dependence like morphine.
Broader Neuropharmacological Profile
- Recent studies show mitragynine and its derivatives may act on multiple brain receptors such as serotonin, dopamine, adenosine, and alpha-2 adrenergic.
- These compounds influence cytochrome P450 enzymes, and their metabolites have opioid-like pathways with potentially reduced sedation and respiratory depression.
- Since 7-OH is formed in the body from mitragynine and produces opioid-like effects, its complete safety profile remains to be fully understood.
Product Example:
Product Name: 7-OH Kratom Chews
Brand Name: Hi On Nature
Product Category: Kratom Extract Chewable Tablets
Conclusion:
The FDA’s recommendation to schedule 7-Hydroxymitragynine marks a pivotal moment in regulating synthetic kratom-derived compounds and aims to mitigate opioid-related public health threats, especially among youth. This initiative distinguishes authentic kratom products from hazardous synthetic derivatives and reinforces nutraceutical product development, innovation in lozenges and chewable nutraceutical formulation, and nutraceutical product formulation standards.
For more updates on regulatory trends and nutraceutical product innovation, visit Food Research Lab.
Let’s create something Innovative and Delicious together
Food Research Lab strives for excellence in new Food, Beverage and Nutraceutical Product Research and Development by offering cutting edge scientific analysis and expertise.